MX359259B - Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida. - Google Patents
Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.Info
- Publication number
- MX359259B MX359259B MX2014002492A MX2014002492A MX359259B MX 359259 B MX359259 B MX 359259B MX 2014002492 A MX2014002492 A MX 2014002492A MX 2014002492 A MX2014002492 A MX 2014002492A MX 359259 B MX359259 B MX 359259B
- Authority
- MX
- Mexico
- Prior art keywords
- choline salt
- inflammatory
- compound
- substituted cyclobutenedione
- cyclobutenedione compound
- Prior art date
Links
- 239000004381 Choline salt Substances 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 235000019417 choline salt Nutrition 0.000 title 1
- -1 cyclobutenedione compound Chemical class 0.000 title 1
- 150000003248 quinolines Chemical class 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract 1
- 229960001231 choline Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530516P | 2011-09-02 | 2011-09-02 | |
| PCT/IB2012/054502 WO2013030803A1 (en) | 2011-09-02 | 2012-08-31 | Choline salt of an anti - inflammatory substituted cyclobutenedione compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014002492A MX2014002492A (es) | 2014-05-28 |
| MX359259B true MX359259B (es) | 2018-09-20 |
Family
ID=47116123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002492A MX359259B (es) | 2011-09-02 | 2012-08-31 | Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9018261B2 (enExample) |
| EP (2) | EP3287438A1 (enExample) |
| JP (3) | JP2014529621A (enExample) |
| KR (1) | KR102024955B1 (enExample) |
| CN (1) | CN103842330B (enExample) |
| BR (1) | BR112014004963A2 (enExample) |
| CA (1) | CA2846510C (enExample) |
| EA (1) | EA201490552A1 (enExample) |
| ES (1) | ES2655942T3 (enExample) |
| HU (1) | HUE035751T2 (enExample) |
| IN (1) | IN2014DN02346A (enExample) |
| MX (1) | MX359259B (enExample) |
| NO (1) | NO2679622T3 (enExample) |
| PL (1) | PL2760821T3 (enExample) |
| PT (1) | PT2760821T (enExample) |
| SI (1) | SI2760821T1 (enExample) |
| WO (1) | WO2013030803A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
| IL275839B2 (en) | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506252A (en) | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| ES2128774T3 (es) | 1994-11-16 | 1999-05-16 | American Home Prod | Diaminociclobuten-3,4-dionas. |
| US5840764A (en) | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AU6250298A (en) | 1997-01-30 | 1998-08-25 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US6166050A (en) | 1998-12-14 | 2000-12-26 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4 |
| FR2815345B1 (fr) | 2000-10-12 | 2002-12-13 | Servier Lab | Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0028844D0 (en) | 2000-11-27 | 2001-01-10 | Celltech Chiroscience Ltd | Chemical compounds |
| US20040132694A1 (en) | 2001-01-16 | 2004-07-08 | Palovich Michael R. | Il-8 receptor antagonists |
| US20040048897A1 (en) | 2001-01-16 | 2004-03-11 | Mccleland Brent | Il-8 receptor antagonists |
| US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| WO2002062761A1 (en) | 2001-02-07 | 2002-08-15 | Abbott Laboratories | Aminal diones as potassium channel openers |
| KR20030088044A (ko) | 2001-03-30 | 2003-11-15 | 스미스클라인 비참 코포레이션 | 페놀-함유 화합물의 합성 방법 |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| CZ20032831A3 (cs) | 2001-04-16 | 2004-03-17 | Schering Corporation | 3,4-Disubstituované cyklobuten-1,2-diony |
| US20050080112A1 (en) | 2001-06-22 | 2005-04-14 | Madsen Lars Siim | Compounds for use in disorders associated with mast cell or basophil acitvity |
| CN100444839C (zh) | 2002-03-18 | 2008-12-24 | 先灵公司 | 式(i)化合物在制备治疗化学激活物中介的疾病的药物中的应用 |
| JP2009513512A (ja) * | 2003-07-09 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | メロキシカムを含む組成物 |
| MY144657A (en) | 2004-01-30 | 2011-10-31 | Schering Corp | Crystalline polymorphs of a cxc-chemokine receptor ligand. |
| AU2005213472A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| GB0407908D0 (en) * | 2004-04-07 | 2004-05-12 | Univ York | Ionic liquids |
| DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| DE602004021404D1 (de) | 2004-12-23 | 2009-07-16 | Gpc Biotech Ag | Quadratsäurederivate mit antiproliferativer Wirkung |
| DE102005001053A1 (de) | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
| KR20070104460A (ko) | 2005-02-10 | 2007-10-25 | 와커 헤미 아게 | 보호된 이소시아네이트기를 가지는 입자를 함유하는 래커 |
| CN101203509B (zh) | 2005-02-16 | 2013-05-08 | 默沙东公司 | 具有cxcr3拮抗剂活性的胺-连接的吡啶基和苯基取代的哌嗪-哌啶 |
| DE102005035742A1 (de) | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| DE102005035741A1 (de) | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate |
| EP2041107A1 (en) | 2006-07-07 | 2009-04-01 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| CA2680177A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| MX2009013276A (es) | 2007-06-06 | 2010-01-25 | Novartis Ag | Compuestos anti-inflamatorios de ciclobutenodiona sustituida. |
| CN101932553A (zh) | 2007-07-03 | 2010-12-29 | 先灵公司 | 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体 |
| CA2694268A1 (en) | 2007-07-05 | 2009-01-08 | Schering Corporation | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
| WO2009073683A2 (en) | 2007-12-04 | 2009-06-11 | Schering Corporation | Methods of treating copd |
| ES2654395T3 (es) | 2007-12-10 | 2018-02-13 | Novartis Ag | Análogos de amilorida espirocíclicos como bloqueantes de ENaC |
| JP2011526888A (ja) * | 2008-07-01 | 2011-10-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 治療薬を標的送達するための経口速溶性薄膜 |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| DK2307376T3 (en) | 2008-08-04 | 2016-01-11 | Merck Patent Gmbh | NOVEL phenylamino ISONIKOTINAMIDFORBINDELSER |
| CA2743639A1 (en) * | 2008-11-14 | 2010-05-20 | Patheon Inc. | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010091543A1 (en) | 2009-02-10 | 2010-08-19 | Merck Sharp & Dohme Corp. | Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists |
-
2012
- 2012-08-31 PT PT127805356T patent/PT2760821T/pt unknown
- 2012-08-31 ES ES12780535.6T patent/ES2655942T3/es active Active
- 2012-08-31 JP JP2014527801A patent/JP2014529621A/ja active Pending
- 2012-08-31 WO PCT/IB2012/054502 patent/WO2013030803A1/en not_active Ceased
- 2012-08-31 CA CA2846510A patent/CA2846510C/en not_active Expired - Fee Related
- 2012-08-31 HU HUE12780535A patent/HUE035751T2/hu unknown
- 2012-08-31 EA EA201490552A patent/EA201490552A1/ru unknown
- 2012-08-31 CN CN201280047528.3A patent/CN103842330B/zh not_active Expired - Fee Related
- 2012-08-31 IN IN2346DEN2014 patent/IN2014DN02346A/en unknown
- 2012-08-31 MX MX2014002492A patent/MX359259B/es active IP Right Grant
- 2012-08-31 KR KR1020147008317A patent/KR102024955B1/ko not_active Expired - Fee Related
- 2012-08-31 US US14/241,306 patent/US9018261B2/en not_active Expired - Fee Related
- 2012-08-31 PL PL12780535T patent/PL2760821T3/pl unknown
- 2012-08-31 BR BR112014004963A patent/BR112014004963A2/pt active Search and Examination
- 2012-08-31 EP EP17191365.0A patent/EP3287438A1/en not_active Withdrawn
- 2012-08-31 SI SI201231173T patent/SI2760821T1/en unknown
- 2012-08-31 EP EP12780535.6A patent/EP2760821B1/en not_active Not-in-force
-
2013
- 2013-06-26 NO NO13173884A patent/NO2679622T3/no unknown
-
2016
- 2016-09-08 JP JP2016175348A patent/JP6612200B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-19 JP JP2018135448A patent/JP2019001787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2655942T3 (es) | 2018-02-22 |
| EP2760821B1 (en) | 2017-10-11 |
| EA201490552A1 (ru) | 2014-11-28 |
| KR20140059264A (ko) | 2014-05-15 |
| US9018261B2 (en) | 2015-04-28 |
| JP6612200B2 (ja) | 2019-11-27 |
| PL2760821T3 (pl) | 2018-04-30 |
| JP2014529621A (ja) | 2014-11-13 |
| CA2846510C (en) | 2019-10-22 |
| SI2760821T1 (en) | 2018-02-28 |
| EP2760821A1 (en) | 2014-08-06 |
| PT2760821T (pt) | 2018-01-11 |
| IN2014DN02346A (enExample) | 2015-05-15 |
| HUE035751T2 (hu) | 2018-08-28 |
| MX2014002492A (es) | 2014-05-28 |
| WO2013030803A1 (en) | 2013-03-07 |
| JP2017025081A (ja) | 2017-02-02 |
| EP3287438A1 (en) | 2018-02-28 |
| CA2846510A1 (en) | 2013-03-07 |
| BR112014004963A2 (pt) | 2017-03-21 |
| US20140206768A1 (en) | 2014-07-24 |
| JP2019001787A (ja) | 2019-01-10 |
| KR102024955B1 (ko) | 2019-09-24 |
| CN103842330B (zh) | 2016-10-19 |
| NO2679622T3 (enExample) | 2018-01-20 |
| CN103842330A (zh) | 2014-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014002492A (es) | Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida. | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| WO2013066839A3 (en) | Compounds and methods | |
| WO2013066835A3 (en) | Compounds and methods | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2012094598A3 (en) | Pharmaceutical compositions of iron for oral administration | |
| CO6940374A2 (es) | Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas | |
| EA201070328A1 (ru) | Соединения триазолопиридина и их применение в качестве ингибиторов ask | |
| EA201690962A1 (ru) | Составы | |
| EA201101190A1 (ru) | Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение | |
| EA201290677A1 (ru) | Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения | |
| EA201291099A1 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
| PH12015500587A1 (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
| BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
| BR112014004435A2 (pt) | inibidores de quinase rock | |
| MX2017001620A (es) | Formas cristalinas de inhibidores de glutaminasa. | |
| UA113750C2 (xx) | Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону | |
| UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
| EA201490223A1 (ru) | Составы на основе дарунавира | |
| NZ735777A (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112013017184A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças | |
| AR092104A1 (es) | LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) | |
| BR112014002915A2 (pt) | inibidores de pde4 suaves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |